All In Biotech

Drug Trial Radar · NCT07857616

SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

SI-B036-ST-101: A Multicenter, Open-Label, Phase 1/1b, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SI-B036 in Adult Patients With Advanced/Metastatic Solid Tumors That Are Refractory to Standard Therapies

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

424

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Oct 2028

Study completion Oct 2029

Sponsor

Lead sponsor
SystImmune Inc.Industry
Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.

Conditions

  • Locally Advanced /Metastatic Solid Tumors
  • Locally Advanced / Metastatic Solid Tumors
  • Metastatic Solid Cancers
  • Non Small Cell Lung Cancer
  • Lung Cancer
  • Melanoma
  • Ovarian
  • NSCLC

Interventions

  • SI-B036Drug

    SI-B036 will be administered on Day 1 by intravenous (IV) infusion every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants with Dose-Limiting ToxicitiesTime frame: 24 months
  2. Participants with Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and Treatment-Emergent Adverse Events (TEAEs)Time frame: 24 months
  3. Participants with abnormal physical examination findingsTime frame: 24 months
  4. Participants with abnormal lab resultsTime frame: 24 months
  5. Participants with abnormal ECG readingTime frame: 24 months
  6. To determine the maximum tolerated dose (MTD) if reached or minimum safe and pharmacologically effective dose (MSED).Time frame: 24 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Yale Cancer Center

    New Haven, Connecticut · Not yet recruiting

  • Florida Cancer Specialists Lake Nona

    Orlando, Florida · Recruiting

  • Florida Cancer Specialists Sarasota

    Sarasota, Florida · Recruiting

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma · Not yet recruiting

  • Sarah Cannon Research Institute - Oncology Partners

    Nashville, Tennessee · Recruiting

  • Mary Crowley Cancer Research

    Dallas, Texas · Recruiting

  • MD Anderson

    Houston, Texas · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.